Axial Spondyloarthritis – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Axial Spondyloarthritis – Drugs In Development, 2023’, provides an overview of the Axial Spondyloarthritis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Axial Spondyloarthritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Axial Spondyloarthritis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Axial Spondyloarthritis
- The report reviews pipeline therapeutics for Axial Spondyloarthritis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Axial Spondyloarthritis therapeutics and enlists all their major and minor projects
- The report assesses Axial Spondyloarthritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Axial Spondyloarthritis
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Axial Spondyloarthritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Axial Spondyloarthritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
3SBio IncAbbVie Inc
Accro Bioscience Suzhou Co Ltd
AIxplorerbio Inc
Akeso Inc
Asia Cell Therapeutics (Shanghai) Co Ltd
Asia Stem Cell Regenerative Pharmaceutical Co Ltd
Aurigene Oncology Ltd
Avesthagen Ltd
Beijing Eastern Biotech Co Ltd
Bio-Thera Solutions Ltd
Biocad
Biogen Inc
Bioviz Technologies Pvt Ltd
BioXpress Therapeutics SA
Bristol-Myers Squibb Co
Celltrion Inc
DNX Biopharmaceuticals Inc
Dyadic International Inc
Eli Lilly and Co
ellennbe GmbH
Foshan Rexie Biotechnology Co Ltd
FunPep Co Ltd
Galapagos NV
Genrix (Shanghai) Biopharmaceutical Co Ltd
Gilead Sciences Inc
Huabo Biopharm (Shanghai) Co Ltd
Hualan Biological Engineering Inc
Iltoo Pharma
Intas Pharmaceuticals Ltd
Izana Bioscience Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
JiangSu Qyuns Therapeutics Co Ltd
Jiangsu Vcare PharmaTech Co Ltd
Johnson & Johnson
JSR Life Sciences LLC
Lanleys International Inc
Livzon Pharmaceutical Group Co Ltd
Lmito Therapeutics Co Ltd
Luye Pharma Group Ltd
Lynk Pharmaceutical Hangzhou Co Ltd
Mabpharm Ltd
Minapharm Pharmaceuticals
MoonLake Immunotherapeutics
Mycenax Biotech Inc
NeuClone Pty Ltd
Nimbus Therapeutics LLC
North China Pharmaceutical Group New Drug Research and Development Co Ltd
Novartis AG
Pharmapraxis
PKU V-Ming (Hefei) Biologics Co Ltd
Qilu Pharmaceutical Co Ltd
RheumaGen LLC
Sandoz Group AG
Shandong Danhong Pharmaceutical Co Ltd
Shanghai Junshi Biosciences Co Ltd
Shanghai Novamab Biopharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shilpa Biologicals Pvt Ltd
Siam Bioscience Co Ltd
SinoCelltech Group Ltd
Sinopharm Group Co Ltd
Suzhou Zelgen Biopharmaceutical Co Ltd
Tianjin Hemay Pharmaceutical Co Ltd
UCB SA
Valin Technologies Ltd
Wuhan Institute of Biological Products Co Ltd
Yatai Institute of Innovative Medicine
Zhejiang Borui Biopharmaceutical Co Ltd